Pack size: Box of 30 Capsules  |  Price is for the whole Box

⚠ Prescription required. This medicine may only be dispensed against a valid prescription.

Generic: Larotrectinib

Form: Capsule 100mg

Indication

Indicated for treatment of patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment

Administration

Capsules or oral solution may be used interchangeably

Adult Dose

Solid Tumors Indicated for treatment of patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment 100 mg PO BID Continue until disease progression or until unacceptable toxicity Hepatic impairment Mild (Child-Pugh A): No dosage adjustment necessary Moderate to severe (Child-Pugh B or C): Reduce starting dose by 50%

Child Dose

Solid Tumors Indicated for treatment of patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment Body surface area (BSA) <1 m²: 100 mg/m² PO BID BSA >1 m²: 100 mg PO BID Continue until disease progression or until unacceptable toxicity

Renal Dose

Renal impairment Mild to severe: No dosage adjustment necessary

Mode of Action

Highly selective inhibitor of tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3; chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines In tumor models, larotrectinib demonstrates antitumor activity in cells by activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK overexpression